What We Claim Is:

1. A method for the prophylaxis or treatment of a hyperlipidemic condition or disorder in a subject which comprises administering a first amount of an apical sodium co-dependent bile acid transporter inhibitor and a second amount of an HMG Co-A reductase inhibitor wherein:

the apical sodium co-dependent bile acid transporter inhibitor is selected from the group consisting of:



;



;









;



;



;



R= 5000 formula weight polyethyleneglycol

;



;



:



;



; and



;

and the pharmaceutically acceptable salts, esters, and prodrugs thereof; and

the first and second amounts of said inhibitors together comprise a therapeutically effective amount of said inhibitors.

2. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

3. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

4. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

5. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

6. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

7. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

8. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

9. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

10. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

11. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

12. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

13. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

14. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

15. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

16. The method of Claim 1 wherein the HMG Co-A reductase inhibitor is selected from the group consisting of mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin, atorvastatin, ZD-4522, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

17. The method of Claim 1 wherein the HMG Co-A reductase inhibitor is selected from the group consisting of atorvastatin, simvastatin, pravastatin, ZD-4522, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

18. The method of Claim 1 wherein the HMG Co-A reductase inhibitor comprises mevastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

19. The method of Claim 1 wherein the HMG Co-A reductase inhibitor comprises atorvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

20. The method of Claim 1 wherein the HMG Co-A reductase inhibitor comprises simvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

21. The method of Claim 1 wherein the HMG Co-A reductase inhibitor comprises pravastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

22. The method of Claim 1 wherein the HMG Co-A reductase inhibitor comprises lovastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

23. The method of Claim 1 wherein the HMG Co-A reductase inhibitor comprises cerivastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

24. The method of Claim 1 wherein the HMG Co-A reductase inhibitor comprises fluvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

25. The method of Claim 1 wherein the HMG Co-A reductase inhibitor comprises ZD-4522, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof.

26. The method of Claim 1 wherein the HMG Co-A reductase inhibitor comprises NK-104, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof.

27. The method of Claim 1 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof; and

the HMG Co-A reductase inhibitor is selected from the group consisting of mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin, atorvastatin, ZD-4522, NK-104, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

28. The method of Claim 27 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises the 4R,5R enantiomer of



or a pharmaceutically acceptable salt, ester or prodrug thereof.

29. The method of Claim 27 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises the racemate of



or a pharmaceutically acceptable salt, ester or prodrug thereof.

30. The method of Claim 28 wherein the HMG Co-A reductase inhibitor is selected from the group consisting of atorvastatin, simvastatin, pravastatin, ZD-4522, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

31. The method of Claim 28 wherein the HMG Co-A reductase inhibitor comprises mevastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

32. The method of Claim 28 wherein the HMG Co-A reductase inhibitor comprises lovastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

33. The method of Claim 28 wherein the HMG Co-A reductase inhibitor comprises simvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

34. The method of Claim 28 wherein the HMG Co-A reductase inhibitor comprises pravastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

35. The method of Claim 28 wherein the HMG Co-A reductase inhibitor comprises fluvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

36. The method of Claim 28 wherein the HMG Co-A reductase inhibitor comprises cerivastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

37. The method of Claim 28 wherein the HMG Co-A reductase inhibitor comprises atorvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

38. The method of Claim 28 wherein the HMG Co-A reductase inhibitor comprises ZD-4522, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof.

39. The method of Claim 28 wherein the HMG Co-A reductase inhibitor comprises NK-104, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof.

40. The method of Claim 28 wherein the apical sodium co-dependent bile acid transporter inhibitor and the HMG Co-A reductase inhibitor are administered in a sequential manner.

41. The method of Claim 28 wherein the apical sodium co-dependent bile acid transporter inhibitor and the HMG Co-A reductase inhibitor are administered in a substantially simultaneous manner.

42. The method of Claim 28 wherein the weight ratio of apical sodium co-dependent bile acid transporter inhibitor to HMG Co-A reductase inhibitor administered is between about 1:50 to about 3:1.

43. The method of Claim 28 wherein said apical sodium co-dependent bile acid transporter inhibitor is administered in a daily dose ranging from about 0.008 mg to about 100 mg,and said HMG Co-A reductase inhibitor is administered in a daily dose ranging from about 0.05 mg to about 100 mg.

44. The method of Claim 28 wherein said apical sodium co-dependent bile acid transporter inhibitor is administered in a daily dose range from about 0.08 mg to about 100 mg.

45. The method of Claim 28 wherein the HMG Co-A reductase inhibitor is administered in a daily dose range from about 0.05 mg to about 100 mg.

46. A composition comprising a first amount of an apical sodium co-dependent bile acid transporter inhibitor selected from the group consisting of



;



;









;



;



;



R= 5000 formula weight polyethyleneglycol

;



;



;



;



; and



;

and the pharmaceutically acceptable salts, esters and prodrugs thereof;

a second amount of the HMG Co-A reductase inhibitor, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof; and

a pharmaceutically acceptable carrier;

wherein the first and second amounts of said inhibitors together comprise a therapeutically effective amount of said inhibitors.

47. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

48. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

49. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

50. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

51. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

52. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

53. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

54. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

55. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

56. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

57. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

58. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

59. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

60. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises



or a pharmaceutically acceptable salt, ester or prodrug thereof.

61. The composition of Claim 46 wherein the HMG Co-A reductase inhibitor is selected from the group consisting of mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin, atorvastatin, ZD-4522, NK-104, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

62. The composition of Claim 46 wherein the HMG Co-A reductase inhibitor is selected from the group consisting of atorvastatin, simvastatin, pravastatin, ZD-4522, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

63. The composition of Claim 46 wherein the HMG Co-A reductase inhibitor comprises mevastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

64. The composition of Claim 46 wherein the HMG Co-A reductase inhibitor comprises atorvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

65. The composition of Claim 46 wherein the HMG Co-A reductase inhibitor comprises simvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

66. The composition of Claim 46 wherein the HMG Co-A reductase inhibitor comprises pravastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

67. The composition of Claim 46 wherein the HMG Co-A reductase inhibitor comprises lovastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

68. The composition of Claim 46 wherein the HMG Co-A reductase inhibitor comprises cerivastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

69. The composition of Claim 46 wherein the HMG Co-A reductase inhibitor comprises fluvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

70. The composition of Claim 46 wherein the HMG Co-A reductase inhibitor comprises ZD-4522, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof.

71. The composition of Claim 46 wherein the HMG Co-A reductase inhibitor comprises NK-104, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof.

72. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises the racemate of



or a pharmaceutically acceptable salt, ester or prodrug thereof; and

the HMG Co-A reductase inhibitor is selected from the group consisting of mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin, atorvastatin, ZD-4522, NK-104, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

73. The composition of Claim 46 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises the 4R,5R enantiomer of



or a pharmaceutically acceptable salt, ester or prodrug thereof; and

the HMG Co-A reductase inhibitor is selected from the group consisting of mevastatin, lovastatin, simvastatin. pravastatin, fluvastatin, cerivastatin, atorvastatin, ZD-4522, NK-104, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

74. The composition of Claim 73 wherein the HMG Co-A reductase inhibitor is selected from the group consisting of atorvastatin, simvastatin, pravastatin, ZD-4522, NK-104, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

75. The composition of Claim 73 wherein the HMG Co-A reductase inhibitor comprises mevastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

76. The composition of Claim 73 wherein the HMG Co-A reductase inhibitor comprises lovastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

77. The composition of Claim 73 wherein the HMG Co-A reductase inhibitor comprises simvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

78. The composition of Claim 73 wherein the HMG Co-A reductase inhibitor comprises pravastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

79. The composition of Claim 73 wherein the HMG Co-A reductase inhibitor comprises fluvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

80. The composition of Claim 73 wherein the HMG Co-A reductase inhibitor comprises cerivastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

81. The composition of Claim 73 wherein the HMG Co-A reductase inhibitor comprises atorvastatin, or a pharmaceutically acceptable salt, ester or prodrug thereof.

82. The composition of Claim 73 wherein the HMG Co-A reductase inhibitor comprises ZD-4522, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof.

83. The composition of Claim 73 wherein the HMG Co-A reductase inhibitor comprises NK-104, or a pharmaceutically acceptable salt, ester, conjugate acid, or prodrug thereof.

84. The composition of Claim 73 wherein the weight ratio of apical sodium co-dependent bile acid transporter inhibitor to HMG Co-A reductase inhibitor is between about 1:50 to about 3:1.

85. A kit containing a first dosage form comprising an ASBT inhibitor and a second dosage form comprising an HMG Co-A reductase inhibitor, wherein the apical sodium co-dependent bile acid transporter inhibitor is selected from the group consisting of:



;



;









;



;



;



R= 5000 formula weight polyethyleneglycol

;



;



;



;



; and



;

and the pharmaceutically acceptable salts, esters and prodrugs thereof.

86. A kit of Claim 85 wherein the apical sodium co-dependent bile acid transporter inhibitor comprises the 4R,5R enantiomer of



or a pharmaceutically acceptable salt, ester or prodrug thereof.

87. A kit of Claim 86 wherein the HMG Co-A reductase inhibitor is selected from the group consisting of mevastatin, lovastatin, simvastatin, pravastatin, fluvastatin, cerivastatin, atorvastatin, ZD-4522, NK-104, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

88. A kit of Claim 86 wherein the HMG Co-A reductase inhibitor is selected from the group consisting of atorvastatin, simvastatin, pravastatin, ZD-4522, and the pharmaceutically acceptable salts, esters, conjugate acids, and prodrugs thereof.

89. The compound having the formula



and the pharmaceutically acceptable salts, esters and prodrugs thereof.